Retention rates of adalimumab, etanercept, and infliximab as first ‐ or second‐line biotherapies for spondyloarthritis patients in daily practice in Auvergne (France)

International Journal of Rheumatic Diseases, EarlyView.

Source: APLAR Journal of Rheumatology - August 31, 2018 Category: Rheumatology Authors: Martin Soubrier , Bruno Pereira , Angelique Fan , Thomas Frayssac , Marion Couderc , Sandrine Malochet ‐Guinamand , Sylvain Mathieu , Zuzana Tatar , Anne Tournadre , Jean‐Jacques Dubost Source Type: research